Back to Browse Journals » Lung Cancer: Targets and Therapy » Volume 1 » Default

Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients

Authors Jean Jacques Dugoua, Ping Wu, Dugald Seely, et al

Published Date July 2010 Volume 2010:1(Default) Pages 85—100

DOI http://dx.doi.org/10.2147/LCTT.S7780

Published 9 July 2010

Jean Jacques Dugoua1, Ping Wu2, Dugald Seely3, Oghenowede Eyawo4, Edward Mills4,5

1Graduate Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada; 2Shanghai Hospital #4, Shanghai, China; 3Department of Clinical Epidemiology, Canadian College of Naturopathic Medicine; 4Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada; 5Faculty of Health Sciences, University of Ottawa, Ottawa, Canada

Background: Non-small-cell lung cancer (NSCLC) is a leading cause of death. Interventions to reduce mortality in patients with NSCLC represent a patient-important field of research. Little is known about interventions used outside the Western world for NSCLC. One intervention widely used in Asia is astragalus-based herbal preparations.

Methods: We conducted a comprehensive systematic review of all published randomized clinical trials (RCTs) evaluating astragalus-based herbal preparations in NSCLC patients. We searched independently, in duplicate, 6 English language electronic databases and 2 Chinese-language databases. We abstracted data independently, in duplicate on studies reporting of methods, survival outcomes, tumor responses, and performance score responses. We applied a random-effects meta-analysis and report outcomes as relative risks (RR) with 95% confidence intervals (CIs).

Results: We included 65 RCTs enrolling 4751 patients. All trials included the herbal preparations plus platinum-based chemotherapy versus chemotherapy alone. We pooled 7 studies (n = 529) reporting on survival at 6 months and found a pooled RR of 0.54 (95% CI, 0.45 to 0.65, P ≤ 0.0001). We included 20 trials in (n = 1520) for survival at 12 months and found a pooled RR of 0.65 (95% CI, 0.54 to 0.79, P ≤ 0.0001). This effect was consistent at 24 and 36 months. When we applied a composite endpoint of any tumor treatment response we pooled data from 57 trials and found a pooled RR of 1.35 in favor of herbal treatment (95% CI, 1.26 to 1.44, P ≤ 0.0001). Statistical heterogeneity was low across trials.

Limitations: The quality of reporting the RCTs was generally poor. There is also reason to believe that studies reported as randomized may not be.
Conclusions: We found a large treatment effect of adding astragalus-based herbal treatment to standard chemotherapy regimens. There is a pressing need for validation of these findings in well-conducted RCTs in a Western setting.

Keywords: astralagus, non-small-cell lung cancer, herbal preparations

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Increased mortality among HIV-positive men on antiretroviral therapy: survival differences between sexes explained by late initiation in Uganda

Kanters S, Nansubuga M, Mwehire D, Odiit M, Kasirye M, Musoke W, Druyts E, Yaya S, Funk A, Ford N, Mills EJ

HIV/AIDS - Research and Palliative Care 2013, 5:111-119

Published Date: 29 May 2013

Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis

Thorlund K, Druyts E, Aviña-Zubieta JA, Mills EJ

Biologics: Targets and Therapy 2012, 6:417-427

Published Date: 3 December 2012

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection

Thorlund K, Druyts E, El Khoury AC, Mills EJ

ClinicoEconomics and Outcomes Research 2012, 4:349-359

Published Date: 16 November 2012

Predictive value of CD4 cell count nadir on long-term mortality in HIV-positive patients in Uganda

Bray S, Gedeon J, Hadi A, Kotb A, Rahman T, Sarwar E, Savelyeva A, Sévigny M, Bakanda C, Birungi J, Chan K, Yaya S, Deonandan R, Mills EJ

HIV/AIDS - Research and Palliative Care 2012, 4:135-140

Published Date: 17 August 2012

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis

Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O'Regan C, Mills EJ

Therapeutics and Clinical Risk Management 2012, 8:105-130

Published Date: 9 March 2012

Multiple treatment comparison meta-analyses: a step forward into complexity

Mills E, Bansback N, Ghement I, Thorlund K, Kelly S, Puhan M, Wright J

Clinical Epidemiology 2011, 3:193-202

Published Date: 27 May 2011

Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis

Mills EJ, Druyts E, Ghement I, Puhan MA

Clinical Epidemiology 2011, 3:107-129

Published Date: 28 March 2011

Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment

Christopher Au-Yeung, Steve Kanters, Erin Ding, et al

Clinical Epidemiology 2011, 3:21-29

Published Date: 19 January 2011

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

Oghenowede Eyawo, Jean Nachega, Pierre Lefebvre, et al

Clinical Ophthalmology 2009, 3:447-456

Published Date: 31 July 2009

Readers of this article also read:

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Nanostructured polyurethane-poly-lactic- co-glycolic acid scaffolds increase bladder tissue regeneration: an in vivo study

Yao C, Hedrick M, Pareek G, Renzulli J, Haleblian G, Webster TJ

International Journal of Nanomedicine 2013, 8:3285-3296

Published Date: 28 August 2013

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite

Takahiro Ueno, Hironori Tsuchiya, Maki Mizogami, Ko Takakura

Journal of Inflammation Research 2008, 1:41-48

Published Date: 13 November 2008